Statement Of Changes In Equity [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166256

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity	55,045,000 EUR	—	—	—	—	476,000 EUR	—	121,513,000 EUR	1,622,000 EUR	64,246,000 EUR	140,000 EUR	—	4,460,000 EUR	—	54,805,000 EUR	476,000 EUR	—	—	48,056,000 EUR	—	3,827,000 EUR	—	103,693,000 EUR	—	2,391,000 EUR	129,000 EUR	—	—	43,226,000 EUR	129,000 EUR	3,827,000 EUR	103,693,000 EUR	476,000 EUR	1,814,000 EUR	59,059,000 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)	—	—	—	10,770,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	11,579,000 EUR	—	—	—	—	—	—	—	—
Other comprehensive income	—	—	—	- EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	- EUR	—	—	—	—	—	—	—	—
Comprehensive income	—	—	—	10,770,000 EUR	10,770,000 EUR	—	—	—	—	—	—	—	—	—	—	—	- EUR	- EUR	—	- EUR	—	—	—	- EUR	—	—	11,579,000 EUR	11,579,000 EUR	—	—	—	—	—	—	—
Issue of equity	—	5,000 EUR	- EUR	14,366,000 EUR	—	—	634,000 EUR	—	—	—	—	—	—	14,995,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Increase (decrease) through share-based payment transactions, equity	—	—	—	560,000 EUR	—	—	—	—	—	—	—	560,000 EUR	—	—	—	—	- EUR	- EUR	—	- EUR	—	576,000 EUR	—	- EUR	—	—	576,000 EUR	- EUR	—	—	—	—	—	—	—